Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry

Viral hepatitis C has long been the most common indication for liver transplantation (LT) in Europe and in the US, with over 20% of all LT candidates on the waiting list having chronic hepatitis C virus infection (HCV). 1-2 Until recently, expected survival rates for HCV infected liver graft recipients was the lowest among all indications, due to severe and rapid HCV recurrence with IFN based therapies giving low cure rates.[1 –3] The approval of first generation direct-acting antiviral agents (DAAs), Telaprevir and Boceprevir, in 2011, marked the beginning of a new era.

Source: Journal of Hepatology - June 22, 2018 Category: Gastroenterology Authors: Luca Saverio Belli, Giovanni Perricone, Rene Adam, Paolo A Cortesi, Mario Strazzabosco, Rita Facchetti, Vincent Karam, Mauro Salizzoni, Rafael Lopez Andujar, Costantino Fondevila, Paolo De Simone, Cristina Morelli, Joan Fabregat-Prous, Didier Samuel, Kosh Source Type: research